Persistent pulmonary hypertension of the newborn is a clinical condition with a low global incidence (2 to 4 per 1000 live births), predominant in premature and post-term infants, yet with significant mortality (up to 33%). The comprehensive management of this syndrome, characterized by persistent and severe hypoxemia due to failure in fetal circulation transitioning to extrauterine life, poses a real challenge in low and middle-income countries. This is primarily due to limited availability and high costs of first-line therapies such as nitric oxide once the diagnosis is established. We present a case from a referral institution in Barranquilla, Colombia, of a 32-week male newborn with early neonatal sepsis, hyaline membrane disease, and marked clinical deterioration, diagnosed with pulmonary hypertension by echocardiography. He was managed with nitric oxide and simultaneous high-frequency mechanical ventilation for 24 hours, showing an adequate response.Additionally, a phosphodiesterase type 5 inhibitor and inodilator were adjunctively administered, resulting in subsequent reduction and normalization of pulmonary pressure.
No takes yet. Share an insight, caveat, or question.
Pumarejomuoz et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: